FDA发布咀嚼片关键质量属性指导原则（中英文对照）
I. INTRODUCTION
II引言
This guidance provides manufacturers of chewable tablets for human use with the Center for Drug Evaluation and Research,s (CDER) current thinking on the critical quality attributes that should be assessed during the development of these drug This guidance also provides recommendations about submitting developmental, manufacturing, and labeling information for chewable tablets that must be approved by CDER before they can be distributed. The recommendations in this guidance apply mainly to new drug applications(NDAs), abbreviated new drug applications (ANDAs), 3 and certain chemistry, manufacturing, and controls (CMC) supplements to these some of there commendations about the submission of developmental information may also apply to investigational new drug applications (INDs). The recommendations about assessing critical quality attributes apply to all chewable tablets for human use, including non-application products.
本指南向生产者提供了药品审评研究中心^口£区)对人用咀嚼片在研发过程 中应评估的关键质量属性的当前想法2。该指南也提供了必须向CDER提交并被其 批准的咀嚼片的研发、生产及说明书信息的建议。该指南的这些建议主要针对新 药申请卬口人$)、仿制药申请(ANDAs) 3和一些化学、生产和质控(CMC)补充 申请4。某些建议同样适合于研究性新药申请(即新药临床申请，INDs)。关于 评估关键质量属性的建议适用于所有人用咀嚼片，包括非申请产品。
Ingeneral, FDA,s guidance documents do not establish legally enforceableresponsibi lities. Instead, guidances describe the Agency's current thinking ona topic and should be viewed only as recommendations, unless specificregulatory or statutory requirements are cited. The use of the word should inAgency guidances means that something is suggested or recommended, but notrequired.
通常，FDA的指导文件不具有法律强制性，指南中描述的主题仅代表FDA机 构目前的看法，只作为建议，除非是引用具体的法规或条例要求。建议或推荐使 用该指导原则，但不是必须的。
IIIBACKGROUND
IV.背景
Chewabletablets are an immediate release (IR) oral dosage form intended to be chewedand then swallowed by the patient rather than swallowed whole. They should be designed to have a pleasanttaste and be easily chewed and swallowed. Chewable tablets should be safe and easy to use in a diverse patientpopulation, pediatric, adult, or elderly patients, who are unable or unwillingto swallow intact tablets due to the size of the tablet or difficulty withswallowing. The availability of safe, easy-to-use dosage forms is important inclinical practice. Chewable tablets are available for many over-the-counter(OTC) and prescription drug products.
咀嚼片是患者经咀嚼后立即释放的口服剂型，而不是整个吞咽。其应被设计 为可口的味道且易于咀嚼和吞咽。咀嚼片应是安全的，易于那些因片子大小或吞 咽困难导致不能或不愿吞服的特殊人、儿童、成年、或老年患者服用。能获得 安全的、易于服用的剂型在临床实践中非常重要。在许多OTC和处方药中均有咀 嚼片。
TheUnited States Pharmacopeia (USP) recognizes and differentiates between twotypes of chewable tablets: (1) thosethat may be chewed for ease of administration, and (2) those that must bechewed or crushed before swallowing to avoid choking and/or to ensure therelease of the active The concepts in this guidance are applicable to both types of chewabletablets.
USP药典中识别和区分两种类型的咀嚼片：(1)可以咀嚼以方便服用的咀 嚼片；(2)必须咀嚼或压碎以避免吞咽窒息和/或确保活性成分充分释放的咀嚼 片5。本指南中的概念适用于这两种类型的咀嚼片。
Adverseevents for chewable tablets can include gastrointestinal (GI) obstructionresulting from patients swallowing whole or incompletely chewed tablets, as wellas tooth damage and denture breakage resulting from excessive tablet A related potential adverse event thatsponsors should also consider is esophageal irritation from chewabletablets. A review of numerous approveddrug product applications for chewable tablets revealed that in certain casescritical quality attributes such as hardness, disintegration, and dissolutionwere
not given as much consideration as may have been warranted. This was evidenced by instances of incompletemonitoring of all relevant critical quality attributes or the use of widelyranging values that were not justified as acceptance criteria. In addition, a wide variation in analyticalprocedures has been ,8,9
咀嚼片的不良反应包括患者整片吞咽或不完全咀嚼导致的胃肠道(GI)阻塞， 以及片剂过硬导致牙齿损伤和假牙破损6。也应考虑咀嚼片引起的食道刺激这一 潜在不良事件。从过去批准的很多咀嚼片来看，许多产品对硬度、崩解时限、溶 出度等关键质量属性的考察仍不充分，例如，对所有相关的关键质量属性监管不 完全，或质量指标范围很宽泛但未证明其在可接受的标准之内。此外，据报道， 分析方法也存在很大差异7,8,9。
Thisguidance describes the critical quality attributes that should be consideredwhen developing chewable tablets and recommends that the selected acceptancecriteria be appropriate and meaningful indicators of product performancethroughout the shelf life of the product.
tablet hardness本指南建议了开发咀嚼片时应考虑的关键质量属性、可选择的合适的可接受 标准、产品有效
期内的有意义的产品性能指标。
VII.讨论
Avariety of physical characteristics should be considered in the manufacturingprocess for chewable tablets. An idealchewable tablet should be:
•Easy to chew
•Palatable （taste masked or of acceptable taste）
•Of appropriate size and shape10
•Able to disintegrate readily to minimize aspiration and facilitate dissolution.
在咀嚼片剂生产工艺中，应考虑各种物理特性。理想的咀嚼片应为：
•易于咀嚼
•味道可口（掩昧或可接受的味道）
•尺寸及形状适中10
•易崩解，以方便吞咽和活性成分溶出
Criticalquality attributes for chewable tablets should include hardness,disintegration, and dissolution, as well as all factors that may influence drugbioavailability and bioequivalence. Inaddition, careful attention should be given to tablet size, thickness, andfriability, as well as taste, which may impact the ability or willingness of apatient to chew the chewable tablet ., a patient may swallow whole, ratherthan chew, a bad tasting tablet）. Nosingle quality characteristic should be considered sufficient to control theperformance of a chewable tablet. Instead, the goal should be to develop theproper combination of these attributes to ensure the performance of thechewable tablet for its intended use.
咀嚼片的关键质量属性包括硬度、崩解时限、溶出度以及其他影响生物利用 度和生物等效性的因素。另外，应重视片剂的形状、厚度、脆碎度和味道，这些 会影响患者服用咀嚼片的能力和意愿（即：患者因味道不好可能整个吞咽，而不 是咀嚼）。充分控制咀嚼片的性能，不能只考虑单一的质量属性，而应考虑质量 属性的合适组合，从而确保咀嚼片达到预期的用途。

版权声明：本站内容均来自互联网，仅供演示用，请勿用于商业和其他非法用途。如果侵犯了您的权益请与我们联系QQ:729038198，我们将在24小时内删除。